The development of EGFR tyrosine kinase inhibitor (TKI), as the therapeutic agent, radically overturned the conventional chemotherapy regimen for lung cancer, which was treated with cytotoxic anticancer agents until then [2,3]. Here, EGFR is linked to lung cancer.